Immunomedics

Immunomedics was a biotechnology company focused on the development of antibody-drug conjugates for the treatment of cancer. In 2020, the company was acquired by Gilead Sciences.[1]

Immunomedics
IndustryBiotechnology
FateAcquired by Gilead Sciences
FoundedJuly 1982 (1982-07)
FounderDavid M. Goldenberg
DefunctOctober 23, 2020 (2020-10-23)
HeadquartersMorris Plains, New Jersey
Websitewww.immunomedics.com 

History

Immunomedics was founded in July 1982 by David M. Goldenberg.[2]

Michael Pehl was named CEO in December 2017 but left due to personal reasons in February 2019.[3] At that time, Dr. Behzad Aghazadeh was named Executive Chairman.[4]

In October 2020, Gilead Sciences acquired the company.[1]

Drugs

  • Epratuzumab is a humanized anti-CD22 monoclonal antibody in phase III trials for pediatric leukemia.
  • Sacituzumab govitecan (IMMU-132 / Trodelvy) is an anti-Trop-2-SN-38 antibody-drug conjugate for breast cancer and solid tumors. It was approved in April 2020 by the FDA for the treatment of adult patients with metastatic triple-negative breast cancer (mTNBC) who have received at least two prior therapies for patients with relapsed or refractory metastatic disease.[5] In 2017, the company scrapped a licensing deal for the drug with Seagen that led to the resignation of founder David M. Goldenberg.[6]
  • Labetuzumab (IMMU-130) is an anti-CEACAM5-SN-38 antibody-drug conjugate in clinical trials for colorectal cancer.
  • Veltuzumab is an anti-CD20 monoclonal antibody for treatment of cancer.
  • Milatuzumab (IMMU-110) is an anti-CD74 monoclonal antibody for autoimmune diseases.
  • IMMU-114 is an anti-HLA-DR for hematological cancers.[7]

References

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.